People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $24.6M | $62.4M | 2024 |
Nathaniel R. Calloway at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nathaniel R. Calloway on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel George | 1 | 4 |
| Richard Cunningham | 1 | 3 |
| Jason R. Aryeh | 1 | 2 |
| Simon Allen | 1 | 2 |
| Areta R. Kupchyk | 1 | 1 |
| Bimal R. Shah | 1 | 1 |
| James R. Merchant | 1 | 1 |
| Karah R. Parschauer | 1 | 1 |
| Kenneth C. Cundy | 1 | 1 |
| Aron F. English | 1 | 1 |
| Aron R. English | 1 | 1 |
| Kenneth R. Lin | 1 | 1 |
| Joseph F. Lawler | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.